Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Drugs"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
dewey-ones:"140 - Specific philosophical schools"
language:"English"
product_txtF_mv:"National Center for Biotechnology Information"
Search alternatives
:
drugs »
drug
Showing
1
-
13
of
13
Search:
'"Drugs"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Arthritis, Rheumatoid /
drug
therapy...
”
Read Now
2
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Arthritis, Rheumatoid /
drug
therapy...
”
Read Now
3
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
Subjects:
“
...
Drug
Costs...
”
Read Now
4
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Drug
Costs...
”
Read Now
5
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Drug
Costs...
”
Read Now
6
Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Wet Macular Degeneration /
drug
therapy...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Wet Macular Degeneration /
drug
therapy...
”
Read Now
8
CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Familial Hypophosphatemic Rickets /
drug
therapy...
”
Read Now
9
CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis
Published 2020
CADTH
Subjects:
“
...Dermatitis, Atopic /
drug
therapy...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis
Published 2020
CADTH
Subjects:
“
...Spondylitis, Ankylosing /
drug
therapy...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)
Published 2020
CADTH
Subjects:
“
...Lupus Erythematosus, Systemic /
drug
therapy...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Multiple Sclerosis, Relapsing-Remitting /
drug
therapy...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Multiple Sclerosis, Relapsing-Remitting /
drug
therapy...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Classification: 140 - Specific philosophical schools
Clear Filter
Language: English
Clear Filter
Collection: National Center for Biotechnology Information
Year of Publication
From:
To:
Classification
140 - Specific philosophical schools
610 - Medicine & health
12
330 - Economics
8
700 - The arts; fine & decorative arts
3
Language
English
Collection
National Center for Biotechnology Information
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
11
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=dewey-ones%3A%22140+-+Specific+philosophical+schools%22&filter%5B%5D=language%3A%22English%22&filter%5B%5D=product_txtF_mv%3A%22National+Center+for+Biotechnology+Information%22&lookfor=%22Drugs%22&type=Subject
Send by Email
×
Loading...